Yaoyanshe, a Chinese clinical research organization (CRO) service provider, has raised RMB300 million (US$42.61 million) in a series C round of financing led by Chinese venture capital firm Eastern Bell Capital and Sequoia Capital China.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?